How is hand, foot, and mouth disease treated?

Hand, foot, and mouth disease (HFMD) is a common childhood infectious disease caused by enteroviruses. Its typical clinical manifestations include rashes, vesicles, and ulcers on the hands, feet, mouth, and buttocks. Most affected children recover well; however, in a minority of cases, the disease progresses rapidly, leading to central nervous system involvement and cardiorespiratory failure. Critically ill patients may succumb to the disease. So, how is HFMD treated? The following addresses this question.

How Is Hand, Foot, and Mouth Disease Treated?

1. Pharmacological Treatment

Antiviral agents demonstrate some therapeutic efficacy. Commonly used drugs include recombinant human interferon-alpha (INF-α) and ribavirin. Recombinant human INF-α is a broad-spectrum antiviral agent effective against nearly all viral infections, including herpesviruses, enteroviruses, and hepatitis viruses. Ribavirin is also a broad-spectrum antiviral drug that exerts anti-EV-A71 activity both in vitro and in vivo. If these medications prove ineffective, vasopressin or levosimendan may be considered as alternative treatments.

2. Hygiene Measures

During outbreaks of HFMD or herpangina, avoid crowded public places. At home, thoroughly clean and disinfect frequently touched surfaces—including floors, tables, chairs, beds, cabinets, and door handles. For children’s hygiene, emphasize frequent handwashing and bathing, regular laundering of clothing, and routine sun-drying of bedding. Infant pacifiers and bottles should be boiled for 20 minutes before reuse; children’s toys should be disinfected regularly.

3. General Management

Ventilate indoor spaces by opening windows at least two to three times daily. Clinical trials have demonstrated that existing inactivated enterovirus vaccines can prevent viral infections causing herpangina, HFMD, and aseptic meningitis—and reduce mortality associated with herpangina and HFMD. The primary immunization schedule consists of two doses administered one month apart. Whether booster immunization is required remains undetermined. Typically, each dose is 0.5 mL administered intramuscularly into the deltoid muscle. Vaccination is recommended for eligible infants and young children.

The above outlines the current approaches to treating hand, foot, and mouth disease. We hope this information is helpful to you.